A148 Ebv Status and Immunosuppressant Use in Ibd Patients Who Subsequently Develop Lymphoma: A Retrospective and Prospective Study

Reeson, Matthew; Ambrosio, Lindsy; Lam, Grace Y.; Fedorak, Richard N.; Dieleman, Levinus A.; Kroeker, Karen I.; Huang, Biao; Peters, Anthea; Halloran, Brendan P.

doi:10.1093/jcag/gwy009.148

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective study by Reeson et al from 2005 to 2015, 14 out of 209 participants enrolled developed lymphoproliferative disorders. 33 Those studied were on biologics, IMM, or combination therapy. All patients with lymphoma were male and, interestingly, only three had a positive serology for EBV.…”

Section: Discussionmentioning

confidence: 99%

<p>Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy</p>

Dahmus¹,

Rosario²,

Clarke³

2020

CEG

View full text Add to dashboard Cite

Anti-tumor necrosis factor alpha (ATA) therapy plays a significant role in the treatment of moderate to severe inflammatory bowel disease (IBD). There are concerns regarding risks associated with their use, including malignancy and, specifically, lymphoma. Many previous studies have sought to determine whether there is a true link between ATA therapy in IBD and development of lymphoma. However they have been hindered by short follow-up times, few cases, and confounding factors such as previous thiopurine exposure. This review seeks to update the literature by evaluating more recent studies assessing the link between ATA monotherapy and lymphoma development. It also summarizes findings of those studies and provides additional clinical guidance pertaining to this class of biologic therapy.

show abstract

Section: Discussionmentioning

confidence: 99%